CPIX
Cumberland Pharmaceuticals Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+27/100
Last price
7.14
▲ 0.05 (0.71%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
7.09
Day high
7.24
Day low
7.06
Volume
22.58K
Market cap
$106.98M
P/E (TTM)
—
52W range
1.85 – 9.28
Trailing performance
Returnvs SPY
1W
-6.67%
-8.6%
1M
+5.15%
+4.0%
3M
+14.24%
+9.7%
6M
+132.57%
+114.4%
YTD
+79.40%
+65.1%
1Y
+128.12%
+111.7%
3Y
+277.78%
+195.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CPIX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
6.23M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 18, 26 | GALANTE JOSEPH C. Director |
STOCK | 1.80K | $5.04K | Direct |
| Mar 18, 26 | BROWN MARTIN S JR Director |
STOCK | 1.80K | $5.04K | Direct |
| Mar 18, 26 | JONES JAMES R Director |
STOCK | 1.80K | $5.04K | Direct |
| Mar 18, 26 | YOUNG CAROLINE R Director |
STOCK | 1.80K | $5.04K | Direct |
| Mar 18, 26 | KROGULSKI KENNETH J Director |
STOCK | 5.80K | $16.24K | Direct |
| Dec 31, 25 | KAZIMI A. J. Chief Executive Officer |
BUY | 270 | $799 | Direct |
| Dec 31, 25 | JONES JAMES R Director |
BUY | 270 | $799 | Direct |
| Dec 31, 25 | YOUNG CAROLINE R Director |
BUY | 66 | $202 | Direct |
| Dec 31, 25 | KROGULSKI KENNETH J Director |
BUY | 1.92K | $5.65K | Direct |
| Nov 28, 25 | KAZIMI A. J. Chief Executive Officer |
BUY | 302 | $664 | Direct |
| Nov 28, 25 | JONES JAMES R Director |
BUY | 302 | $664 | Direct |
| Nov 28, 25 | YOUNG CAROLINE R Director |
BUY | 75 | $170 | Direct |
| Nov 28, 25 | KROGULSKI KENNETH J Director |
BUY | 2.03K | $4.42K | Direct |
| Oct 31, 25 | KAZIMI A. J. Chief Executive Officer |
BUY | 299 | $1.02K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROWN MARTIN S JR |
Director | 10.30K | Stock Award(Grant) |
GALANTE JOSEPH C. |
Director | 63.66K | Stock Award(Grant) |
JONES JAMES R |
Director | 46.86K | Stock Award(Grant) |
KAZIMI A. J. |
Chief Executive Officer | 5.70M | Purchase |
KROGULSKI KENNETH J |
Director | 302.34K | Stock Award(Grant) |
YOUNG CAROLINE R |
Director | 35.11K | Stock Award(Grant) |
Fundamentals
Market cap$106.98M
Enterprise value$107.50M
Revenue (TTM)$44.30M
Gross profit$37.64M
EBITDA$1.10M
Net income$-3.20M
EPS (TTM)$-0.62
Free cash flow$-191.17K
Total cash$3.86M
Total debt$4.71M
Book value / share$1.16
Shares outstanding14.98M
Float8.70M
Short % of float2.88%
Dividend yield0.00%
Beta (5Y)0.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E51.00
PEG ratio1.67
Price / sales—
Price / book6.13
EV / revenue2.43
EV / EBITDA98.02
Gross margin84.95%
Operating margin-1898.65%
Profit margin-24.64%
Return on equity-14.39%
Return on assets-2.91%
Debt / equity27.56
Current ratio0.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $44.52M | $37.87M | $39.55M | $42.01M | +17.6% |
| Operating revenue | $40.40M | $36.54M | $37.51M | $40.68M | +10.6% |
| Cost of revenue | $6.67M | $6.59M | $6.07M | $9.12M | +1.2% |
| Gross profit | $37.85M | $31.28M | $33.49M | $32.89M | +21.0% |
| Research & development | $5.57M | $4.82M | $5.83M | $6.69M | +15.6% |
| Selling, general & admin | $31.05M | $28.15M | $29.10M | $26.84M | +10.3% |
| Total operating expense | $40.65M | $37.71M | $43.04M | $38.60M | +7.8% |
| Operating income | -$2.79M | -$6.43M | -$9.55M | -$5.70M | +56.6% |
| Net interest income | -$19.24K | -$271.06K | -$381.01K | -$487.59K | +92.9% |
| Pre-tax income | -$2.81M | -$6.47M | -$6.28M | -$5.58M | +56.5% |
| Tax provision | $40.26K | -$22.67K | $45.77K | $68.85K | +277.6% |
| Net income | -$2.84M | -$6.48M | -$6.28M | -$5.57M | +56.2% |
| Net income to common | -$2.84M | -$6.48M | -$6.28M | -$5.57M | +56.2% |
| Basic EPS | -0.19 | -0.46 | -0.44 | -0.38 | +58.7% |
| Diluted EPS | -0.19 | -0.46 | -0.44 | -0.38 | +58.7% |
| EBIT | -$2.32M | -$5.86M | -$5.62M | -$5.00M | +60.5% |
| EBITDA | $2.97M | $182.42K | $2.49M | $332.92K | +1,528.5% |
| Basic shares | 14.85M | 14.06M | 14.30M | 14.56M | +5.6% |
| Diluted shares | 14.85M | 14.06M | 14.30M | 14.56M | +5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.44M | $17.96M | $18.32M | $19.76M | -36.3% |
| Cash & short-term investments | $11.44M | $17.96M | $18.32M | $19.76M | -36.3% |
| Accounts receivable | $16.94M | $11.70M | $9.76M | $13.16M | +44.8% |
| Inventory | $6.23M | $4.00M | $4.61M | $9.86M | +55.6% |
| Total current assets | $37.06M | $36.45M | $35.71M | $45.87M | +1.7% |
| Property, plant & equipment | $8.61M | $6.45M | $7.04M | $5.50M | +33.4% |
| Goodwill & intangibles | $14.94M | $18.89M | $23.52M | $31.50M | -20.9% |
| Total assets | $76.82M | $75.58M | $81.78M | $92.93M | +1.6% |
| Total current liabilities | $36.74M | $31.62M | $27.98M | $28.58M | +16.2% |
| Current debt | — | $5.10M | — | — | — |
| Long-term debt | $5.24M | $10.18M | $12.78M | $16.20M | -48.5% |
| Total debt | $10.18M | $20.57M | $18.43M | $20.96M | -50.5% |
| Total liabilities | $52.28M | $53.04M | $52.52M | $56.95M | -1.4% |
| Retained earnings | -$26.80M | -$23.97M | -$17.49M | -$11.21M | -11.8% |
| Shareholder equity | $24.88M | $22.85M | $29.60M | $36.27M | +8.9% |
| Working capital | $315.35K | $4.83M | $7.73M | $17.29M | -93.5% |
| Net tangible assets | $9.94M | $3.97M | $6.08M | $4.76M | +150.6% |
| Shares issued | 14.96M | 13.95M | 14.12M | 14.37M | +7.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$2.86M | -$6.44M | -$6.33M | -$5.65M | +55.5% |
| Depreciation & amortisation | $5.29M | $6.04M | $5.77M | $5.33M | -12.5% |
| Stock-based compensation | $408.32K | $301.89K | $365.04K | $447.50K | +35.3% |
| Change in working capital | $2.16M | $1.29M | $4.63M | $10.44M | +67.3% |
| Operating cash flow | $4.93M | -$612.19K | $6.09M | $8.45M | +905.7% |
| Capital expenditure | -$182.31K | -$179.71K | -$453.05K | -$2.07M | -1.4% |
| Investing cash flow | -$4.71M | $57.84K | -$105.69K | -$13.67M | -8,236.8% |
| Share buybacks | -$263.48K | -$579.05K | -$740.53K | -$1.05M | +54.5% |
| Financing cash flow | -$6.75M | $196.90K | -$7.42M | -$2.06M | -3,525.8% |
| Free cash flow | $4.75M | -$791.90K | $5.64M | $6.38M | +699.9% |
| End cash position | $11.44M | $17.96M | $18.32M | $19.76M | -36.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $166.46K | $9.13M | $13.68M | $8.29M | $380.80K | — | -98.2% |
| Operating revenue | $166.46K | $8.96M | $13.49M | $7.99M | $380.80K | — | -98.1% |
| Cost of revenue | — | $1.93M | $2.24M | $988.76K | $2.01M | $1.43M | — |
| Gross profit | — | $7.20M | $11.44M | $7.30M | $8.83M | $10.29M | — |
| Research & development | $772.16K | $1.46M | $1.55M | $1.25M | $837.40K | — | -47.1% |
| Selling, general & admin | $2.55M | $7.62M | $10.25M | $7.01M | $2.66M | — | -66.6% |
| Total operating expense | $3.33M | $10.33M | $12.81M | $9.27M | $3.50M | — | -67.8% |
| Operating income | -$3.16M | -$3.13M | -$1.37M | -$1.97M | -$3.12M | — | -1.0% |
| Net interest income | $60.16K | -$7.81K | -$20.98K | $21.88K | $127.02K | — | +870.5% |
| Pre-tax income | -$3.10M | -$3.14M | -$1.39M | -$1.94M | -$2.99M | — | +1.2% |
| Tax provision | $3.87K | $3.87K | $23.25K | $5.67K | $5.67K | — | -0.0% |
| Net income | -$4.28M | -$3.29M | -$1.41M | -$1.94M | -$740.74K | — | -30.0% |
| Net income to common | -$4.28M | -$3.29M | -$1.41M | -$1.94M | -$740.74K | — | -30.0% |
| Basic EPS | -0.27 | -0.22 | -0.09 | -0.13 | -0.05 | — | -22.7% |
| Diluted EPS | -0.27 | -0.22 | -0.09 | -0.13 | -0.05 | — | -22.7% |
| EBIT | -$3.10M | -$3.05M | -$1.28M | -$1.83M | -$2.99M | — | -1.6% |
| EBITDA | -$3.09M | -$1.49M | $47.84K | $1.57M | -$2.99M | — | -107.6% |
| Basic shares | 14.98M | 14.96M | 14.96M | 14.96M | 14.96M | — | +0.1% |
| Diluted shares | 14.98M | 14.96M | 14.96M | 14.96M | 14.96M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.86M | $11.01M | $11.44M | $15.20M | $16.09M | — | -64.9% |
| Cash & short-term investments | $3.86M | $11.01M | $11.44M | $15.20M | $16.09M | — | -64.9% |
| Accounts receivable | $13.42M | $14.26M | $16.94M | $10.43M | $10.32M | — | -5.9% |
| Inventory | $29.93K | $5.45M | $6.23M | $2.93M | $3.22M | — | -99.5% |
| Total current assets | $33.64M | $32.79M | $37.06M | $29.94M | $31.21M | — | +2.6% |
| Property, plant & equipment | $7.53M | $7.86M | $8.61M | $7.86M | $7.42M | — | -4.1% |
| Goodwill & intangibles | $43.80K | $13.71M | $14.94M | $15.92M | $16.90M | — | -99.7% |
| Total assets | $62.88M | $71.00M | $76.82M | $65.90M | $67.91M | — | -11.4% |
| Total current liabilities | $35.19M | $34.49M | $36.74M | $24.31M | $23.97M | — | +2.0% |
| Long-term debt | — | $5.24M | $5.24M | $5.24M | $5.24M | $5.24M | — |
| Total debt | $4.71M | $10.07M | $10.18M | $10.24M | $10.34M | — | -53.2% |
| Total liabilities | $45.77M | $49.69M | $52.28M | $40.10M | $40.23M | — | -7.9% |
| Retained earnings | -$34.37M | -$30.09M | -$26.80M | -$25.39M | -$23.45M | — | -14.2% |
| Shareholder equity | $17.44M | $21.64M | $24.88M | $26.12M | $27.99M | — | -19.4% |
| Working capital | -$1.55M | -$1.70M | $315.35K | $5.63M | $7.23M | — | +8.6% |
| Net tangible assets | $17.39M | $7.93M | $9.94M | $10.20M | $11.09M | — | +119.4% |
| Shares issued | 14.98M | 14.98M | 14.96M | 14.96M | 14.96M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.27M | -$3.29M | -$1.43M | -$1.95M | -$735.21K | — | -30.0% |
| Depreciation & amortisation | -$1.01M | $1.56M | $1.33M | $3.40M | -$757.68K | — | -164.6% |
| Stock-based compensation | $77.87K | $106.84K | $172.16K | $81.26K | $80.69K | — | -27.1% |
| Change in working capital | $1.50M | $2.00M | -$30.27K | $4.08M | -$3.01M | — | -25.1% |
| Operating cash flow | $168.74K | $387.02K | $3.02K | $187.18K | $843.80K | — | -56.4% |
| Capital expenditure | -$1.78M | -$19.16K | -$43.84K | -$53.82K | — | -$1.23M | -9,197.6% |
| Investing cash flow | -$1.93M | -$61.17K | -$3.07M | -$690.84K | $285.86K | — | -3,049.1% |
| Share buybacks | $0 | -$61.00K | $0 | -$10.44K | -$7.17K | — | +100.0% |
| Financing cash flow | -$5.39M | -$763.30K | -$681.74K | -$386.88K | -$150.80K | — | -605.8% |
| Free cash flow | -$1.61M | $367.87K | -$40.82K | $133.36K | $1.99M | — | -538.3% |
| End cash position | $3.86M | $11.01M | $11.44M | $15.20M | $16.09M | — | -64.9% |
Options analytics
Put / call volume
0.43
Call-heavy session
Put / call open interest
0.16
Positioning, not flow
Max pain
1.00
-86.0% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
564
Contracts, this expiry
Put volume
245
Contracts, this expiry
Heaviest call OI
5.00
789 contracts
Heaviest put OI
1.00
109 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2021 | -0.07 | -0.00 | +98.4% |
| Mar 2021 | -0.07 | 0.07 | +200.0% |
| Dec 2020 | -0.01 | 0.01 | +200.0% |
| Sep 2020 | -0.07 | 0.02 | +128.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders41.60%
Held by institutions16.56%
Institutions holding39
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.59
-5.92% from price
SMA 20
7.28
-1.97% from price
SMA 50
7.41
-3.65% from price
SMA 100
6.78
+5.28% from price
SMA 200
5.32
+34.29% from price
EMA 12
7.42
-3.77% from price
EMA 26
7.38
-3.29% from price
EMA 50
7.22
-1.15% from price
RSI (14)
45.9
Neutral
MACD (12,26,9)
0.04
Hist -0.04
ATR (14)
0.51
7.13% of price
Realised vol 30D
89.8%
Annualised
Bollinger upper
8.38
20, 2σ
Bollinger lower
6.19
20, 2σ
50 / 200 cross
Golden
7.41 vs 5.32
Trend bias
Above 200
+34.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
89.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.2%
Peak to trough
Max drawdown 5Y
-84.7%
Peak to trough
ATR 14
0.51
7.13% of price
Beta (reported)
0.04
5Y monthly, from filing
Short interest
Shares short
252.45K
Prior 326.21K
Change vs prior
-22.6%
Shorts covering
% of float
2.88%
Normal
% of shares out
1.68%
Against total outstanding
Days to cover
4.0
Liquid
Float
8.70M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 3, 19 | B. Riley Securities | MAINTAINED | — | Buy |
| Nov 18, 19 | B. Riley Securities | MAINTAINED | — | Buy |
| Aug 17, 18 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Apr 17, 18 | B. Riley Securities | INITIATED | — | Buy |
| Apr 10, 13 | UBS | MAINTAINED | — | Neutral |
| Nov 12, 12 | UBS | MAINTAINED | — | Neutral |
| Nov 9, 12 | Wells Fargo | DOWNGRADE | Outperform | Market Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateAug 3, 2026
Next pay dateJul 31, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-25
Proxy Statements
DEFM14A · 2026-05-26
Headlines
Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...
GuruFocus.com · 63d ago
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 63d ago
Cumberland: Q2 Earnings Snapshot
Associated Press · 64d ago
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
PR Newswire · 64d ago
Possible Generic Drug Tariffs and 2 Microcaps
Zacks · 68d ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
PR Newswire · 71d ago
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
Zacks · 84d ago
Cumberland Declares Special Dividend, Approves $5 Million Share Buyback
MT Newswires · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.